Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 343.9 Million | USD 462.6 Million | 4.30% | 2022 |
The global Newcastle Disease Vaccine market size is set for rapid growth over the forecast period. In terms of revenue, the global Newcastle Disease Vaccine market accounted for USD 343.9 Million in 2022 and is expected to reach USD 462.6 Million by 2030, growing at a CAGR of 4.3% during the forecast period.
Newcastle disease is an infectious disease that affects many avian species, both domestic and wild; it is transmissible to humans. There are several Newcastle disease vaccines available on the market that are suitable for commercial chickens. The I-2 Newcastle disease vaccine (Thermostable Vaccine) has been produced for local or regional development and to combat Newcastle disease in village chicken. After storage for one to two hours at room temperature, several Newcastle disease vaccinations worsen. This renders them unfit for use in villages where the vaccine will need to be transported at room temperature for hours or, in some cases, days. The I-2 vaccine also needs long-term storage in cold temperature, but the vaccine will not deteriorate as easily as conventional vaccines when the vaccine is delivered to the field.
Increasing need to control disease outbreaks to drive industry expansion
Raising vaccines to curb outbreaks of avian disease and increasing demand for food items linked to poultry are mainly driving the global Newcastle disease vaccine market. In addition, the market is driven by growing awareness among veterinary practitioners about animal vaccination, increasing meat consumption, and rising government food safety initiatives. For example, according to the Middle East Rating Agency, the Qatar government established central food laboratories in April 2019 with various food safety procedures and analyses to ensure that consumers are delivered contamination-free, healthy, and high-quality meat products.
The growing population of poultry is also driving the Newcastle disease vaccine market demand for products. Consumption of contaminated meat threatens human health, making it imperative that birds are vaccinated prior to use. The rapid spread of illnesses and the lack of treatment options are the key challenges faced by poultry farms. Vaccination is necessary to avoid such situations. Compulsory vaccination of other domesticated & agricultural animals, increased inventories of poultry, improved productivity of livestock, and an increased emphasis on food safety contribute significantly to market growth.
High cost of vaccine development and limited availability of skilled professionals might restrict market growth
The global Newcastle Disease Vaccine Market faces several restraints that could hinder its growth in the coming years. One of the major restraints is the high cost of vaccine development, which may discourage new players from entering the market. Another key restraint is the stringent regulations governing the development, production, and distribution of vaccines, which can delay the approval and commercialization of new vaccines. Additionally, the limited availability of skilled personnel and infrastructure in certain regions may hamper the growth of the market. Finally, the presence of alternative treatments and preventive measures, such as biosecurity measures and dietary supplements, may reduce the demand for Newcastle disease vaccines, particularly in regions with limited resources.
Introduction of new, advanced, and improved vaccines create ample opportunities for the market
The Newcastle disease vaccine industry offers several opportunities that could drive its growth in the coming years. One of the major opportunities is the increasing prevalence of the Newcastle disease in poultry, which is driving the demand for effective and safe vaccines globally. Another key opportunity is the growing awareness of the benefits of vaccination among farmers, veterinarians, and poultry producers, which is increasing the uptake of Newcastle disease vaccines. Additionally, the introduction of new and advanced vaccines that offer improved efficacy, safety, and convenience is expected to further fuel the growth of the market. Finally, the increasing investments by governments and private organizations in animal health and welfare, particularly in emerging economies, are expected to create new opportunities for market players to expand their reach and market share.
Limited access to new, improved vaccines and emergence of new strains might act as a challenge
The Newcastle disease vaccine industry faces several challenges that could hinder its growth and development in the coming years. One of the major challenges is the emergence of new and more virulent strains of the Newcastle disease virus, which could render existing vaccines ineffective and increase the need for more advanced and effective vaccines. Another key challenge is the limited access to vaccines in certain regions, particularly in developing countries with limited resources and infrastructure.
The global Newcastle disease vaccine market is segmented based on vaccine type, species, and region.
Based on vaccine type, the market is bifurcated into Live Attenuated, Inactivated, and Thermostable. The live attenuated vaccine segment held the largest market share in 2022 and is further predicted to cite the fastest CAGR during the forecast period. Live Attenuated Vaccines (LAV) have been widely used and preferred over other vaccine types due to their effectiveness, low cost, and ability to provide long-lasting immunity. LAVs have been shown to confer broad-spectrum immunity against different strains of Newcastle disease viruses, making them a popular choice among poultry farmers. These factors drive the growth of the segment during the forecast period.
Based on species, the market is segmented based on chicken, duck, goose, And others. The chicken segment held the dominating market share in 2022 and is further expected to occupy a significant CAGR during the forecast period. Newcastle Disease Virus (NDV) is a significant threat to the chicken industry, leading to significant economic losses due to high mortality rates and reduced egg production. Therefore, the demand for Newcastle Disease Vaccines is high among chicken farmers, making this segment the most profitable in the market. However, vaccines for other bird species such as ducks and geese are also in demand, especially in regions where these birds are raised commercially or for domestic purposes.
Report Attributes | Report Details |
---|---|
Report Name | Newcastle Disease Vaccine Market Research Report |
Market Size in 2022 | USD 343.9 Million |
Market Forecast in 2030 | USD 462.6 Million |
Growth Rate | CAGR of 4.3% |
Number of Pages | 220 |
Key Companies Covered | Merial, QYH Biotech, CEVA, Yebio, Ringpu (Tianjin) Bio-Pharmacy Co., Ltd, Bayer AG, Hipra, Anicon Labor GmbH, Chengdu Tech-bank Biological Products Co., Ltd., Ringpu Bio-Technology Co., Ltd., MSD Animal Health, Nisseiken Co., Harbin Veterinary Research Institute, Merck Animal Health, ChengDu Tecbond, DHN, Zoetis, Elanco (Lohmann), CAVAC, Vaksindo, FATRO, and others. |
Segments Covered | By Vaccine Type, By Species, And By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America to rule the global market in terms of market share
Due to increased consumption of poultry-related food items, consumer perception of food safety, and a high incidence of avian diseases, North America has dominated the global Newcastle disease vaccine market and is expected to sustain its lead over the forecast period. In addition, the booming production of poultry meat has played a key role in the region's dominance. According to the United Nations Food and Agriculture Organization (UNFAO), the U.S. is the world's largest producer of poultry meat, accounting for 18.0 percent of total production. Furthermore, the adoption of poultry vaccines in the country is being driven by joint strategic projects and acquisitions to further foster better avian health. Market development is also being fueled by increased investment in animal welfare and favorable reimbursement policies.
The European market is expected to emerge as a strong contender because of government measures for research & development activities and rapid progress in animal husbandry practices.
The Asia Pacific market is expected to report the fastest growth rate over the forecast period, due to growing awareness of poultry vaccines and the increase in the number of vaccination awareness programs in the region.
Some of the key players in the global Newcastle Disease Vaccine market are:
By Vaccine Type
By Species
By Region
FrequentlyAsked Questions
Newcastle disease is an infectious disease that affects many avian species, both domestic and wild; it is transmissible to humans.
The global Newcastle disease vaccine market is predicted to increase at a CAGR of 4.3% during the forecast period.
The global Newcastle disease vaccine market was worth around USD 343.9 million in 2022 and is expected to reach USD 462.6 million by 2030.
The global market for Newcastle vaccine disease is driven by the increasing demand for poultry products and the need for effective vaccines to prevent economic losses in the poultry industry. The market growth is also supported by the growing awareness among poultry farmers about the benefits of vaccination programs, advancements in vaccine technology & production methods, and government initiatives to control the spread of the disease.
North America held the largest share in the global Newcastle disease vaccine market in 2022 and is likely to continue the same trend during the forecast period. This is due to factors such as the increasing demand for poultry products, rising investments in animal health research, and government support to control the spread of the disease.
Some of the major companies operating in the global Newcastle disease vaccine market include Merial, QYH Biotech, CEVA, Yebio, Ringpu (Tianjin) Bio-Pharmacy Co., Ltd, Bayer AG, Hipra, Anicon Labor GmbH, Chengdu Tech-bank Biological Products Co., Ltd., Ringpu Bio-Technology Co., Ltd., MSD Animal Health, Nisseiken Co., Harbin Veterinary Research Institute, Merck Animal Health, ChengDu Tecbond, DHN, Zoetis, Elanco (Lohmann), CAVAC, Vaksindo, FATRO, and others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed